Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study.
Jordan Elizabeth RobertsCordelia BurnRebecca E SadunEmily A SmithermanScott E WenderferMary Beth F SonPublished in: Lupus (2023)
In our cohort of pediatric patients with lupus and moderate disease activity treated with belimumab for ≥12 months, daily oral glucocorticoid doses were significantly lower 6 and 12 months after belimumab initiation than baseline. Use in patients with active nephritis was uncommon. Further research is needed in a large, multicenter cohort to determine the real-world effectiveness of belimumab in children and develop guidelines for use.
Keyphrases
- systemic lupus erythematosus
- disease activity
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- randomized controlled trial
- systematic review
- young adults
- high intensity
- physical activity
- rheumatoid arthritis
- clinical practice
- cross sectional
- adipose tissue
- metabolic syndrome
- insulin resistance